Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.  In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in.

Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial

ENGLEWOOD, Colo. , April 20, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today announced the receipt of written responses from the United States Food and Drug Administration (FDA) pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.

AMPIO PROVIDES REGULATORY UPDATE

Anika Therapeutics

FAT Brands

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

New Strong Sell Stocks for April 7th

Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript

Cash and Cash Equivalents of $34 Million Expected to Fund Current Operations into 2H 2023 Company to host Conference Call Tuesday, March 29, 2022, at 4:30pm EDT ENGLEWOOD, Colo. , March 29, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021.

Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.

Why Ampio Pharmaceuticals Stock Is Rising Today

ENGLEWOOD, Colo. , March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST.

Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

ENGLEWOOD, Colo., March 9, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, will attend the 34th Annual ROTH Conference, which is being held in Laguna Niguel, California from March 13-15, 2022.

Ampio Pharmaceuticals to Participate at the 34th Annual Roth Conference

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the modified Intent-to-Treat (mITT) population in the Company's AP-013 study, a Phase 3 clinical trial of the company's lead candidate, Ampion™, in patients suffering from severe osteoarthritis of the knee (OAK).

Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, announced that the Company will be hosting a webinar and conference call today at 4:30pm EST to provide an update on clinical and regulatory progress in osteoarthritis of the knee.

Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar

ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq.

Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes

ENGLEWOOD, Colo., Jan. 6, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it will present at the H.C.

Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference

Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

ENGLEWOOD, Colo., Dec. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 25,000,000 shares of the Company's common stock ( the "Shares") and warrants to purchase 15,000,000 shares of the Company's common stock (the "Warrants" and, together with the Shares, the "Securities") at a combined purchase price of $0.90 per Share in a registered direct offering.

AMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERING

ENGLEWOOD, Colo., Nov. 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business update call with its chairman and CEO, Mike Martino, at 4:30 p.m.

Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1

ENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call with its CEO and Chairman, Michael Martino, who will provide a corporate and business on Wednesday, December 1, 2021, at 4:30 pm EDT/ 2:30 pm MT.

Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino

ENGLEWOOD, Colo., Nov. 22, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced that Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediately.

Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave

The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)

Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript

ENGLEWOOD, Colo., Nov. 10, 2021 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today reported results for the three- and nine-month periods ended September 30, 2021 and provided a corporate overview and business update.

Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update

ENGLEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT.

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update

ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointments of Howard Levy, M.B.B.Ch.

Ampio Pharmaceuticals Strengthens Management Team and Board of Directors

ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) in the Phase II AP-019 clinical trial in India.

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Seanergy Maritime Hlds

Waitr Holdings Inc

Investing in penny stocks right now? Check these three small caps out for your watchlist The post Best Penny Stocks For Retail Traders to Buy?

Best Penny Stocks For Retail Traders to Buy? 3 For Your List

CASI Pharmaceuticals

ConforMIS

Clovis Oncology

AB Corporate Bond ETF

Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Ampio Pharmaceuticals Inc Stock (AMPE)